Date: March 26, 2020
Time: 14.00-17.00, registration from 13.30
Location: Helio GT30, Grev Turegatan 30, Stockholm
With presentations from PMDD practitioners and patients, as well as Asarina Pharma’s leading researchers and managers, the day will give a broad picture of PMDD, what the most meaningful clinical effects for a treatment are, and how the company's upcoming Phase IIb data will be evaluated and presented.
Doctor Paula Briggs: Lead study investigator, Liverpool Woman’s Hospital, consultant in sexual and reproductive health.
Professor Torbjörn Bäckström: Founder and CSO Asarina Pharma, Professor Dept. Clinical Sciences, Obstetrics and Gynecology Umeå University.
Karin Ekberg, PhD: Chief Operating Officer, Asarina Pharma.
Paula ‘Fenjima’ Manrique: PMDD patient and advocate, writer, speaker, regular guest as Gaming Expert on Swedish TV4:s Nyhetsmorgon.
Doctor Peter Nordkild: CEO Asarina Pharma.
The event will also offer some insights into Asarina Pharma's other ongoing research into menstrual migraine and Tourette syndrome.
Please register for R&D Day at the following link: https://financialhearings.com/event/12602/register/live_event
We look forward to meeting you!